Receptor News and Research

RSS

Lipid pathways driving diabetes and heart disease risk in South Asians

Identifying lipid-linked genetic pathways in Asian Indians offers insights into diabetes and heart disease, crucial for developing ancestry-specific therapies.

28 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

GLP-1 weight loss is driven mainly by fat loss, not muscle loss

GLP-1-based therapies helped adults with overweight or obesity lose weight mainly by reducing fat mass and visceral adipose tissue, while lean body mass losses were generally modest. The findings suggest these treatments can support higher-quality weight loss when paired with individualized care, nutrition, and resistance training.

27 Apr 2026

Estrogen loss after menopause impacts heart health through gene regulation

Virginia Tech scientists at the Fralin Biomedical Research Institute say the increased risk of cardiovascular disease after menopause may stem not only from declining hormone levels, but also from how those changes influence gene activity.

27 Apr 2026

Glycocalyx modification boosts immune cell targeting against B lymphoma

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B lymphoma, addressing limitations such as high costs and restricted antigen specificity in current treatments.

25 Apr 2026

Fucosylated IgG drives adipose tissue dysfunction during aging

A study published in Engineering has identified fucosylated immunoglobulin G (IgG) as a key mediator contributing to adipose tissue dysfunction during aging, offering insights into age-related metabolic disorders and potential therapeutic targets.

25 Apr 2026

People judge weight loss more harshly when GLP-1 drugs are involved, study finds

In four pre-registered studies across Belgium, the US, and the UK, people judged anti-obesity medication users as putting in less effort and, in turn, viewed them as less moral, competent, warm, and deserving than non-users. The findings suggest that effort moralization may help drive stigma around GLP-1-based weight-loss treatment, even when medication is used alongside diet and exercise.

23 Apr 2026

Kenyan bat coronavirus uses human CEACAM6 to enter cells, raising spillover concerns

Researchers screened a phylogenetically diverse panel of alphacoronavirus spike proteins and found that a heart-nosed bat coronavirus from Kenya can use human CEACAM6 to enter cells.

23 Apr 2026

Vitamin D may prevent diabetes in people with certain genes

More than two in five U.S. adults has prediabetes, a condition marked by higher-than-normal blood sugar levels that often leads to type 2 diabetes.

23 Apr 2026

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR).

23 Apr 2026

High levels of gut bacterial toxin linked to increased lupus nephritis risk

The body's immune reaction to increased levels of a toxic molecule, part of a bacterial species in the human gut, may reveal who is most at risk of developing lupus nephritis, according to a new study led by NYU Langone Health.

23 Apr 2026

New antibody mechanism selectively suppresses harmful immune responses

The immune system is our frontline protection against infection, continually searching for and destroying unknown pathogens.

22 Apr 2026

Microglia actively shape glioblastoma growth and tumor spread

Glioblastoma, the most common and most aggressive brain tumor type in adults, remains difficult to treat because it can infiltrate surrounding brain tissue and spread far beyond the main tumor.

21 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

NHS grant funds study on the use of weight-loss drugs for treating PCOS

Dr. Shagaf Bakour, a gynecologist and director of medical education at Aston Medical School, has won an NHS research grant to investigate the use of weight-loss drugs in the treatment of polycystic ovary syndrome (PCOS).

21 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

Targeting glutamine metabolism enhances CAR-macrophage cancer therapy

Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, which impairs their antitumor function.

20 Apr 2026

CBD shows promise, but this review warns the hype is outpacing the science

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.

20 Apr 2026